Literature DB >> 7483145

Gammopathy associated with advanced prostate carcinoma.

M Abdul1, N M Hoosein.   

Abstract

As proteinuria was found to be common in patients with prostate cancer, the possible presence of elevated urinary immunoglobulin (Ig) levels was investigated. First morning urine samples from 30 patients with androgen-dependent (AD) and 43 patients with androgen-independent (AI) prostate cancer were tested. A sensitive, solid-phase radioimmunoassay and polyclonal antibody interacting with IgG, IgA and IgM was used to screen urine samples. Compared with 15 normal, age-matched, healthy subjects, urinary Ig levels were elevated in 10 of 30 (33%) patients with AD prostate cancer and in 24 of 43 (56%) patients with AI prostate cancer. In the latter group, five of seven (71%) patients with prostatic SCC had elevated urinary Igs. Further analysis of ten urine samples containing increased urinary Ig levels, using antibodies specific for each heavy chain (gamma, alpha and mu) as well as each light chain (kappa and lambda), indicated that patients with a high or moderate elevation in Ig levels had polyclonal gammopathy, whereas those with a low increase in urinary Igs had monoclonal gammopathy of the IgG class. These results indicate, for the first time, a high frequency of an abnormal increase in Ig levels in patients with advanced prostatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7483145     DOI: 10.1007/bf00389571

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  11 in total

Review 1.  Current concepts on monoclonal gammopathies.

Authors:  R A Kyle
Journal:  Aust N Z J Med       Date:  1992-06

Review 2.  The monoclonal gammopathies (paraproteins).

Authors:  R A Kyle; J A Lust
Journal:  Adv Clin Chem       Date:  1990       Impact factor: 5.394

Review 3.  Laboratory monitoring of myeloma proteins.

Authors:  R A Kyle; J P Garton
Journal:  Semin Oncol       Date:  1986-09       Impact factor: 4.929

4.  Immunoglobulin clonality analysis. Resolution of ambiguities in immunofixation electrophoresis results by high-resolution, two-dimensional electrophoretic analysis of paraprotein bands eluted from agarose gels.

Authors:  H H Harrison; K L Miller; A Abu-Alfa; S J Podlasek
Journal:  Am J Clin Pathol       Date:  1993-11       Impact factor: 2.493

5.  The World Health Organization histological typing of lung tumours. Second edition.

Authors: 
Journal:  Am J Clin Pathol       Date:  1982-02       Impact factor: 2.493

6.  Prostatic cancer presenting monoclonal gammopathy: report of two cases.

Authors:  M Tsutsumi; T Hara; R Fukasawa; K Koiso
Journal:  Hinyokika Kiyo       Date:  1993-06

Review 7.  Clinical use of tumor markers in oncology.

Authors:  E L Jacobs; C M Haskell
Journal:  Curr Probl Cancer       Date:  1991 Nov-Dec       Impact factor: 3.187

8.  Immunoglobulin binding factor: a new tumor marker for prostatic tumors.

Authors:  N Maeda; M Kamada; T Daitoh; M Maegawa; K Hirano; T Aono; T Shiotsu; H Kanayama; S Kagawa; S Futaki
Journal:  Prostate       Date:  1994       Impact factor: 4.104

9.  Chemotherapy for small cell carcinoma of prostatic origin.

Authors:  R J Amato; C J Logothetis; R Hallinan; J Y Ro; A Sella; F H Dexeus
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

10.  The frequency of M-components in sera of patients with solid malignant neoplasms.

Authors:  A Talerman; W G Haije
Journal:  Br J Cancer       Date:  1973-04       Impact factor: 7.640

View more
  1 in total

Review 1.  Monoclonal gammopathy in prostate carcinoma: a case report and review of literature.

Authors:  Samik Pramanik; Md Jahangir Gazi; Anjan Kumar Das; Nirod Baran Debnath; Salil K Pal
Journal:  J Med Case Rep       Date:  2018-10-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.